EP1926482A2 - Pharmazeutische form mit verzögerter ph-unabhängiger wirkstoff-freisetzung für wirkstoffe mit stark ph-abhängiger löslichkeit - Google Patents

Pharmazeutische form mit verzögerter ph-unabhängiger wirkstoff-freisetzung für wirkstoffe mit stark ph-abhängiger löslichkeit

Info

Publication number
EP1926482A2
EP1926482A2 EP06776644A EP06776644A EP1926482A2 EP 1926482 A2 EP1926482 A2 EP 1926482A2 EP 06776644 A EP06776644 A EP 06776644A EP 06776644 A EP06776644 A EP 06776644A EP 1926482 A2 EP1926482 A2 EP 1926482A2
Authority
EP
European Patent Office
Prior art keywords
water
solid pharmaceutical
pharmaceutical formulation
formulation according
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06776644A
Other languages
English (en)
French (fr)
Inventor
Claudia Guthmann
Heiko Kranz
Ralph Lipp
Torsten Wagner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Priority to EP06776644A priority Critical patent/EP1926482A2/de
Publication of EP1926482A2 publication Critical patent/EP1926482A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the invention relates to a solid pharmaceutical formulation for a sustained pH- independent active ingredient release comprising at least one layer of one or more water- insoluble polymers, at least one layer of one or more pH-dependent water-soluble polymers and an active ingredient-containing core, where the core comprises an active ingredient having strong pH-dependent water solubility and at least one osmotically active ingredient.
  • Active ingredients having strong pH-dependent water solubility are for example substances which have very poor solubility at basic pH values, normally having a solubility in water of less than 0.1 mg/ml , whereas the solubility at acidic pH values (pH ⁇ 4) extends up to values of 1 mg/ml or higher.
  • pH-dependent water-soluble active ingredients can also be defined as substances having a difference of at least 10-fold in the water solubility at acidic and basic pH values.
  • an active ingredient having strong pH-dependent solubility in water is (2R) -1- ( (4-chloro- 2- (ureido) phenoxy) methyl) carbonyl-2 -methyl -4- (4-fluoro- benzyl) piperazine or a salt thereof.
  • Salts thereof are, for example, the hydrochloride, dihydrogen phosphate, hydrogen sulphate, sulphate, mesylate, ethylsulphonate, malate, fumarate and tartrate.
  • the following invention further relates to a matrix pellet for a sustained pH- independent active ingredient release comprising at least one layer of one or more water-insoluble polymers in which the pore-forming substances are present and are dissolved out after contact with the aqueous medium and thus form a microporous membrane, and comprising at least one layer of one or more pH-dependently water-soluble polymers, and an active ingredient-containing core, where the core comprises piperazineurea and at least one water- soluble ionic substance from the group of magnesium chloride, magnesium sulphate, lithium chloride, sodium chloride, potassium chloride, lithium sulphate, sodium sulphate, potassium sulphate, lithium phosphate, sodium phosphate, potassium phosphate, ammonium chloride, ammonium sulphate, ammonium phosphate as osmagent .
  • Multiparticulate systems may be for example granular particles, pellets or mini tablets. These may be packed into hard or soft gelatin capsules, and compressed to tablets The original formulation usually disintegrates into many subunits in the stomach. The minidepots then gradually pass from the stomach into the intestine. The minidepots are moreover normally able to pass through the pylorus when the sphincter is closed.
  • Sustained release formulations are medicaments which can be administered orally and have a longer-lasting effect of the medicament. In these cases, the active pharmaceutical ingredient is released slowly.
  • An elementary osmotic pump for example, are tablets which consist of an osmotically active tablet core which is coated with a semipermeable membrane which comprises a release orifice.
  • the tablet core may comprise an osmotically active medicinal substance or, in the case of a medicinal substance of low osmotic activity, osmotically active additives, also generally defined as osmagents.
  • osmotically active additives also generally defined as osmagents.
  • the object of an EOP is controlled active ingredient release, achieving 0 order release kinetics.
  • the amount of medicinal substance released from the pharmaceutical form per unit time remains the same.
  • a precondition for an EOP is a moderately water-soluble active ingredient .
  • Push and pull osmotic pumps (PPOPs) have been established also to allow controlled release of slightly soluble medicinal substances.
  • These comprise multichamber tablet systems whose core comprises an osmotic active ingredient compartment and a swellable osmotically active polymer, with the two compartments being separated by an elastic diaphragm.
  • the entire tablet core is in turn enveloped by an SPM which comprises a release orifice on the active ingredient containing side.
  • systems which operate osmotically such as the elementary osmotic pump (EOP) and push and pull osmotic pumps (PPOP) release at least moderately water-soluble active ingredients from tablets which consist of a semipermeable membrane around an osmotically active core which comprises at least one substance having an osmotic effect (osmagent) and, in the case of the PPOP, an expanding polymer push compartment .
  • EOP elementary osmotic pump
  • PPOP push and pull osmotic pumps
  • the active constituent is released through at least one orifice in the semipermeable membrane.
  • the essential aim of osmotic pumps as known in the state of the art is 0 order active ingredient release.
  • CPOPs were also developed in order to replace the elaborate manufacture of the above-described systems in which release orifices must be bored by drilling machines or lasers .
  • CPOP formulations have a water-insoluble polymer membrane into which water-soluble ingredients are incorporated and, after contact with the aqueous medium, are dissolved out and thus form a microporous membrane which is now permeable by medium and active ingredient.
  • the osmotic tablet core is enveloped by an insoluble polymer membrane into which water-soluble substances have been incorporated. After the pharmaceutical form is introduced into the medium, these water-soluble substances are dissolved out.
  • the active ingredient release depends in particular on the water-solubility of the medicinal substance and thus shows a pH-dependent release for pH-dependently soluble active ingredients.
  • Delayed release pellet formulations have been described for osmagent-containing matrix pellet cores which have been coated with a semipermeable membrane. This membrane is stretched owing to the swelling of the core, resulting after a lag time in pores which make the membrane permeable by medium and active ingredient and thus bring about a delayed active ingredient release.
  • Such delayed release formulations are utilized for accurately targeted active ingredient release in the GI tract or release according to chrono- pharmacological aspects or are used when the kinetics of absorption of a medicinal substance are non-linear.
  • Asymmetric membranes which can be applied to tablets and also to pellet cores bring about an improved release of active ingredients of low solubility.
  • these formulations also do not show pH- independent active ingredient release for pH-dependently soluble substances.
  • a pH- independent release has been described for such systems when pH adjusters have been incorporated in the core formulation for buffering.
  • Such excipients either acids or bases alter the pH within the formulation to such an extent that the active ingredient solubility is improved, even in pH-unfavourable media.
  • Multilayer coating combinations have been described for the combination of water-soluble and water- insoluble polymer layers, where the water-soluble polymers do not show pH-dependent solubility and thus any control of the release of pH-dependently soluble active constituents either.
  • the present invention relates to a solid pharmaceutical formulation for a sustained pH- independent active ingredient release comprising at least one layer of one or more water- insoluble polymers, at least one layer of one or more pH-dependent water-soluble polymers and an active ingredient-containing core, where the core comprises an active ingredient having strong pH-dependent solubility in water and at least one osmagent .
  • the layer of one or more water-insoluble polymers comprises pore- forming substances which are dissolved out after contact with the aqueous medium and thus form a microporous membrane.
  • the layer of one or more pH-dependent water-soluble polymers is the outer layer on the solid pharmaceutical formulation, and the layer of one or more water-insoluble polymers is the inner one.
  • the present invention further relates to a matrix pellet for a sustained pH- independent active ingredient release comprising at least one inner layer of one or more water- insoluble polymers in which pore- forming substances are present and, after contact with the aqueous medium, are dissolved out and thus form a microporous membrane, and comprising at least one outer layer of one or more pH-dependent water-soluble polymers, and an active ingredient -containing core, where the core comprises piperazineurea and at least one water-soluble ionic substance from the group of magnesium chloride, magnesium sulphate, lithium chloride, sodium chloride, potassium chloride, lithium sulphate, sodium sulphate, potassium sulphate, lithium phosphate, sodium phosphate, potassium phosphate, ammonium chloride, ammonium sulphate, ammonium phosphate.
  • osmotically active substances Only by use of osmotically active substances according to the present invention was a pH- independent active ingredient release achieved. Only an osmotically active addition to the core formulation with a high active ingredient loading, for example up to 90% w/w, preferably up to 60% w/w, based on the mass of the core formulation brings about rapid penetration of medium into the core, followed by the formation of a saturated active ingredient solution which, driven by the osmotic pressure, is forced out of the solid pharmaceutical formulation.
  • a high active ingredient loading for example up to 90% w/w, preferably up to 60% w/w
  • a pH-dependently water-soluble polymer layer is necessary even for a core with osmagent .
  • pore- forming substances may be an addition to the water- insoluble membrane.
  • the membrane Owing to incorporated pore formers, the membrane rapidly becomes permeable not only by medium but also by the active ingredient.
  • the rapid permeability of the water- insoluble membrane is very important in particular for active ingredients having a very low solubility in water.
  • the release of the active substance from the solid pharmaceutical formulation according to the present invention is not only pH- independent but also substantially increased by comparison with known pharmaceutical formulations without osmagent in the core .
  • Figure 1 a preferred embodiment of the solid pharmaceutical formulation according to the present invention .
  • Figure 2 a solid pharmaceutical formulation of Figure 1 with pH-dependently water-soluble polymer layer without osmagent in the core.
  • Formulations with pH-dependently water-soluble polymer layer without osmagent in the core show a very greatly reduced active ingredient release in the medium with the actually highest active ingredient solubility.
  • Figures 3a-3c show release investigations on a solid pharmaceutical formulation of Figure 1 with pH-dependently water-soluble polymer layer without osmagent in the core.
  • the release investigations were carried out in a USPXXV basket apparatus at 100 revolutions per minute and with a medium temperature of 37°C ( ⁇ 0.5 0 C).
  • the media used were 0.1 N HCl and phosphate buffer of pH 6.8. Quantification took place by HPLC.
  • Figure 4 a solid pharmaceutical formulation of Figure 1 without pH-dependently water-soluble polymer layer with osmagent in the core .
  • Figure 5 a solid pharmaceutical formulation of Figure 1 with pH-dependently water-soluble polymer layer and osmagent in the core.
  • a pH-independent active ingredient release was achieved through the introduction of osmotically active substances.
  • Figures 6a- 6c and 7a- 7c show release investigations on the solid pharmaceutical formulation of Figure 1 with pH-dependently water-soluble polymer layer with osmagent in the core ( Figure 6a-6c for Examples 2 and Figures 7a-7c for Examples 3) .
  • the release investigations were carried out in a USPXXV basket apparatus at 100 revolutions per minute and with a medium temperature of 37°C (+ 0.5 0 C) .
  • the media used were 0.1 N HCl and phosphate buffer of pH 6.8. Quantification took place by HPLC.
  • the solid pharmaceutical formulation 1 according to the invention (Fig. 1) comprises at least one layer 3 of one or more water-insoluble polymers, at least one layer 2 of one or more pH-dependently water-soluble polymers .
  • the formulation core 5 according to the invention is loaded with a strong pH-dependent water-soluble active ingredient 6 and at least one osmagent 7.
  • the layer 3 of one or more water- insoluble polymers comprises pore- forming substances 4 which are dissolved out after contact with the aqueous medium 8 and thus form a microporous membrane .
  • the one or more pore-forming substances 4 may be water- soluble polymers or other water-soluble additions such as salts or sugars.
  • the one or more pore-forming substances 4 may be selected from the group comprising for example polyvinylpyrrolidone (PVP) , crospovidone (crosslinked N-vinyl-2-pyrrolidone, Cl-PVP), hydroxypropylmethyl- cellulose (HPMC) , polyethylene glycol (PEG) , hydroxy- propylcellulose (HPC) and mixtures thereof.
  • PVP polyvinylpyrrolidone
  • crospovidone crosslinked N-vinyl-2-pyrrolidone
  • HPMC hydroxypropylmethyl- cellulose
  • PEG polyethylene glycol
  • HPC hydroxy- propylcellulose
  • Formulations of an active ingredient -containing core without osmagent and of two layers of polymer (Fig. 2), where the inner layer consisted of a water- insoluble and the outer layer of a pH-dependently water-soluble polymer, still showed a strong pH-dependent release of the active substance.
  • a piperazineurea-containing core without osmagent according to Figure 2 with higher solubility at acidic pH values (pH ⁇ 4) was unable to achieve an efficient active ingredient release (Fig. 3a-c) .
  • the active ingredient release of piperazineurea in medium of pH 1 was less than expected.
  • a pH- independently active ingredient release is not achieved even with a formulation without pH-dependently water-soluble polymer film (Fig. 4) .
  • a dry powder mixture was prepared by introducing the sieved ingredients into a M ⁇ ller drum with subsequent mixing in a Turbula mixer.
  • the dry powder mixture was subsequently moistened in a high-speed mixer, the amount of binder solution necessary for extrusion and spheronization having been determined by preliminary tests.
  • the resulting moist granules were then extruded in an extruder and rounded in a spheronizer.
  • the produced pellets in a preferred embodiment of the invention were then dried in a fluidized bed (GPCGl from Glatt) . After sieving, the pellet fraction from 0.8 mm to 1.25 mm diameter was used for further production.
  • GPCGl fluidized bed
  • the polymer dispersions were applied in a fluidized bed granulator with Wurster insert, with application of the first layer being followed by a brief drying pause and then application of the second layer.
  • the formulation layer of one or more water-insoluble polymers is for example from 1% to 40% w/w, preferably from 1% to 10% w/w, preferably from 2% to 5% w/w based on the total mass of formulation.
  • the water- insoluble polymers may be selected from the group comprising polyvinyl acetate; alkylcelluloses , acrylate-methacrylate copolymers, vinyl acetate-methacrylate copolymers and -acrylate copolymers; ethylcellulose, ethyl acrylate-methyl methacrylate copolymer and ethyl acrylate-methyl acrylate-trimethylammoniummethyl methacrylate chloride terpolymer and mixtures thereof.
  • pore- forming substances were used in the formulation layer of one or more water- insoluble polymers (subcoating formulation) .
  • the one or more pore- forming substances may be water-soluble polymers or other water-soluble additions such as salts or sugars.
  • the one or more pore- forming substances may be selected from the group comprising for example polyvinylpyrrolidone (PVP) , crospovidone (crosslinked N-vinyl-2 -pyrrolidone, Cl-PVP) , hydroxypropylmethylcellulose (HPMC) , polyethylene glycol (PEG) , hydroxypropylcellulose (HPC) and mixtures thereof .
  • the formulation layer of one or more pH-dependent water-soluble polymers is for example from 1% to 40% w/w, preferably from 1% to 10% w/w, preferably from 2% to 5% w/w, based on the total mass of formulation.
  • the acid- insoluble polymers may be selected from the group comprising acrylate-methacrylic acid copolymers, carboxyalkylcelluloses, cellulose acetate phthalates, cellulose acetate succinates, cellulose acetate trimelliates, hydroxyalkylcellulose phthalates, hydroxyalkylcellulose acetate succinates, vinyl acetate phchalates, vinyl acetate succinate; ethyiacryiate- methacrylic acid copolymer, methyl methacrylate- methacrylic acid copolymer, methyl methacrylate-methyl acrylate-methacrylic acid copolymer, carboxymethyl- cellulose, cellulose acetate phthalate; hydroxypropyl- methylcellulose phthalate, hydroxypropylmethylcellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, polyvinyl acetate phthalate, shellac and mixtures thereof .
  • Alkali-insoluble polymers which can be used are acrylate-methacrylate copolymers, basic natural polysaccharides, dimethylaminoethyl methacrylate-methyl methacrylate-butyl methacrylate terpolymer, chitosan and mixtures thereof.
  • Osmotically active substances which can be used for targeted pH- independent active ingredient release are water-soluble ionic or nonionic substances and hydrophilic polymers, alone or as mixture.
  • the water-soluble ionic substance may be selected from the group comprising magnesium chloride, magnesium sulphate, lithium chloride, sodium, chloride, potassium chloride, lithium sulphate, sodium sulphate, potassium sulphate, lithium phosphate, sodium phosphate, potassium phosphate, sodium carbonate, ammonium chloride, ammonium sulphate, ammonium phosphate alone or as mixture .
  • the content of water-soluble ionic osmotic substance in the core may be from 2% to 50% w/w based on the total mass of cores and in particular from 2% to 20% w/w based on the total mass of cores .
  • a water-soluble nonionic substance may be selected from the group comprising for example sucrose, mannitol, lactose, dextrose, sorbitol, alone or as mixture.
  • the concent of water-soluble nonionic osmotic substance in the core may be from 2% to 50% w/w based on the total mass of cores and in particular from 10% to 40% w/w based on the total mass of cores .
  • the hydrophilic polymers may be selected from the group comprising hydroxypropylmethylcellulose (HPMC) , hydroxypropylcellulose (HPC), xanthan gum, alginate, sodium carboxylmethylcellulose , polyvinylpyrrolidone
  • PVP polyvinylpyrrolidone
  • Cl-PVP Cl -polyvinylpyrrolidone
  • Water-soluble ionic substances preferably used according to the present invention are those which achieve a high osmotic effect with relatively small amounts.
  • cellulose or cellulose derivatives as additional formulating agent for influencing the mechanical strength of the pharmaceutical form.
  • Microcrystalline cellulose is particularly advantageous. Examples
  • Example 1 Production of coated matrix pellets with pH-dependent water-soluble polymer layer without osmagent in the core (Fig. 3a-c; state of the art)
  • Formulation layer of one or more water-insoluble polymers (subcoating formulation) (% w/w) : Polyvinyl acetate 70%
  • Polyvinylpyrrolidone 30% Coating level of the subcoating formulation 5% w/w based on total mass of pellets.
  • Formulation layer of one or more pH-dependent water- soluble polymers topcoating formulation (% w/w) :
  • Microcrystalline cellulose and active ingredient are sieved and mixed in a Turbula mixer for 20 minutes.
  • the dry powder mixture is mixed with the required amount of binder solution (water) in a high-speed mixer.
  • the resulting moist granules are subsequently extruded through a 1 mm screen in an extruder.
  • the produced extrudate is rounded in portions in a spheronizer at 400 rpm.
  • the pellets are subsequently dried in a GPCGl fluidized bed granulator at 60 0 C.
  • the matrix pellet cores are equilibrated at 50 0 C in a GPCGl fluidized bed granulator with Wurster insert for 10 minutes. Then a 15% (w/w) polyvinyl acetate dispersion which comprises the water-soluble pore former polyvinylpyrrolidone is applied at an inlet air temperature of 50 0 C.
  • the pH-dependently soluble methacrylic acid-ethyl acrylate copolymer (15% w/w) is sprayed on at an inlet air temperature of 50 0 C.
  • the coated matrix pellets are equilibrated at 40 0 C for 24 h.
  • Example 2 Production of coated matrix pellets with pH-dependent water-soluble polymer layer with osmagent (KCl) in the core (Fig. 6a-c)
  • Formulation layer of one or more water-insoluble polymers (subcoating formulation) (% w/w) :
  • Formulation layer of one or more pH-dependent water- soluble polymers (topcoating formulation) (% w/w) : Methacrylic acid-ethyl acrylate copolymer 100% Coating level of the topcoating formulation (% w/w) : 0% (Fig. 6a); 2.5% (Fig. 6b); 5% (Fig. 6c) based on cocai mass of pellets.
  • Microcrystalline cellulose and active ingredient are sieved and mixed in a Turbula mixer for 10 minutes.
  • Sieved potassium chloride is added and mixed in the Turbula mixer for a further 10 minutes.
  • the dry powder mixture is mixed with the required amount of binder solution (water) in a high-speed mixer.
  • the resulting moist granules are subsequently extruded through a 1 mm screen in an extruder.
  • the produced extrudate is rounded in portions in a spheronizer at 400 rpm.
  • the pellets are subsequently dried in a GPCGl fluidized bed granulator at 6O 0 C.
  • the matrix pellet cores are equilibrated at 50 0 C in a GPCGl fluidized bed granulator with Wurster insert for 10 minutes. Then a 15% (w/w) polyvinyl acetate dispersion which comprises the water-soluble pore former polyvinylpyrrolidone is applied at an inlet air temperature of 50 0 C.
  • the pH-dependently soluble methacrylic acid-ethyl acrylate copolymer (15% w/w) is sprayed on at an inlet air temperature of 50 0 C.
  • the coated matrix pellets are equilibrated at 40 0 C for 24 h.
  • Example 3 Production of coated matrix pellets with pH-dependent water-soluble polymer layer with osmagent (NaCl) in the core (Fig. 7a-c) Core formulation (% w/w) :
  • Formulation layer of one or more water-insoluble polymers (subcoating formulation) (% w/w) : Polyvinyl acetate 70%
  • Polyvinylpyrrolidone 30% Coating level of the subcoating formulation 5% w/w based on total mass of pellets.
  • Formulation layer of one or more pH-dependent water- soluble polymers topcoating formulation:
  • Coating level of the topcoating formulation (% w/w) :
  • Microcrystalline cellulose and active ingredient are sieved and mixed in a Turbula mixer for 10 minutes.
  • Sieved sodium chloride is added and mixed in the Turbula mixer for a further 10 minutes.
  • the dry powder mixture is mixed with the required amount of binder solution (water) in a high-speed mixer.
  • the resulting moist granules are subsequently extruded through a 1 mm screen in an extruder.
  • the produced extrudate is rounded in portions in a spheronizer at 400 rpm.
  • the pellets are subsequently dried in a GPCGl fluidized bed granulator at 60 0 C.
  • the matrix pellet cores are equilibrated at 50 0 C in a GPCGl fluidized bed granulator with Wurster insert for 10 minutes. Then a 15% (w/w) polyvinyl acetate dispersion which comprises the water-soluble pore former polyvinylpyrrolidone is applied at an inlet air temperature of 50 0 C.
  • the pH-dependently soluble methacrylic acid-ethyl acrylate copolymer (15% w/w) is sprayed on at an inlet air temperature of 50 0 C.
  • the coated matrix pellets are equilibrated at 40 0 C for 24 h.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP06776644A 2005-08-05 2006-08-02 Pharmazeutische form mit verzögerter ph-unabhängiger wirkstoff-freisetzung für wirkstoffe mit stark ph-abhängiger löslichkeit Withdrawn EP1926482A2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06776644A EP1926482A2 (de) 2005-08-05 2006-08-02 Pharmazeutische form mit verzögerter ph-unabhängiger wirkstoff-freisetzung für wirkstoffe mit stark ph-abhängiger löslichkeit

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05090228A EP1749519A1 (de) 2005-08-05 2005-08-05 Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
US70642805P 2005-08-09 2005-08-09
PCT/EP2006/007783 WO2007017219A2 (en) 2005-08-05 2006-08-02 Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
EP06776644A EP1926482A2 (de) 2005-08-05 2006-08-02 Pharmazeutische form mit verzögerter ph-unabhängiger wirkstoff-freisetzung für wirkstoffe mit stark ph-abhängiger löslichkeit

Publications (1)

Publication Number Publication Date
EP1926482A2 true EP1926482A2 (de) 2008-06-04

Family

ID=35448205

Family Applications (2)

Application Number Title Priority Date Filing Date
EP05090228A Withdrawn EP1749519A1 (de) 2005-08-05 2005-08-05 Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit
EP06776644A Withdrawn EP1926482A2 (de) 2005-08-05 2006-08-02 Pharmazeutische form mit verzögerter ph-unabhängiger wirkstoff-freisetzung für wirkstoffe mit stark ph-abhängiger löslichkeit

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP05090228A Withdrawn EP1749519A1 (de) 2005-08-05 2005-08-05 Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit

Country Status (11)

Country Link
EP (2) EP1749519A1 (de)
JP (1) JP2009503011A (de)
CN (1) CN101257895A (de)
AR (1) AR055110A1 (de)
CA (1) CA2617280A1 (de)
DO (1) DOP2006000184A (de)
GT (1) GT200600353A (de)
PE (1) PE20070464A1 (de)
TW (1) TW200738285A (de)
UY (1) UY29728A1 (de)
WO (1) WO2007017219A2 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2612989A1 (en) * 2006-05-08 2007-11-08 Mcneil-Ppc, Inc. Osmotic dosage form
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
EP2598123A1 (de) * 2010-07-27 2013-06-05 Norgine BV Zusammensetzungen
CN103093211B (zh) * 2013-01-27 2015-09-30 西安电子科技大学 基于深度核信息图像特征的人体运动跟踪方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
HUT77530A (hu) * 1994-05-06 1998-05-28 Pfizer Inc. Azitromicint tartalmazó, szabályozott hatóanyag-felszabadítású dózisformák
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10211289A1 (de) * 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H. VOGELPOEL ET AL: "Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: Verapamil hydrochloride, propranolol hydrochloride, and atenolol", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 93, no. 8, 1 August 2004 (2004-08-01), pages 1945 - 1956, XP055000367, ISSN: 0022-3549, DOI: 10.1002/jps.20131 *
P. AUGUSTIJNS AND M.E. BREWSTER (EDS.): "Solvents Systems and their selection in pharmaceutics and biopharmaceutics", vol. VI, 1 January 2007, SPRINGER AAPS PRESS, New York, ISBN: 978-0-387-69149-7, article W-Q TONG: "Chapter 5 Practical aspects of solubililty determination in pharmaceutical preformulation", pages: 137 - 149 *
See also references of WO2007017219A2 *

Also Published As

Publication number Publication date
CN101257895A (zh) 2008-09-03
WO2007017219A2 (en) 2007-02-15
TW200738285A (en) 2007-10-16
PE20070464A1 (es) 2007-06-07
JP2009503011A (ja) 2009-01-29
WO2007017219A3 (en) 2007-06-28
AR055110A1 (es) 2007-08-08
DOP2006000184A (es) 2007-05-31
EP1749519A1 (de) 2007-02-07
CA2617280A1 (en) 2007-02-15
GT200600353A (es) 2007-03-14
UY29728A1 (es) 2007-02-28

Similar Documents

Publication Publication Date Title
JP2750150B2 (ja) 改良されたコアー膜付着性質を有する医薬的に許容される活性剤を含む浸透性連続分散性経口投写システム
EP2877162A1 (de) Orale darreichungsformen für modifizierte freisetzung mit ruxolitinib
US10213389B2 (en) Controlled release compositions comprising a combination of isosorbide dinitrate and hydralazine hydrochloride
JP2009501777A (ja) 胃保持型製剤およびそれらの製造方法
JP2008535877A (ja) 良性前立腺肥大症の治療用の組合せ
KR20080037680A (ko) 1-(4-클로로아닐리노)-4-(4-피리딜메틸)프탈라진 및 ｐｈ조절제를 포함하는 고체 제약학적 조성물
WO2007017219A2 (en) Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
US20160058788A1 (en) Multiple ppi dosage form
US20050208135A1 (en) Monocompartment osmotic controlled drug delivery system
US20070087056A1 (en) Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
HK1214136A1 (zh) 硝酸氨基烷基酯的延长释放组合物
JP2007520421A (ja) 経口投与用放出制御型薬物送達システム
JP2006507298A (ja) 経口持続放出型錠剤、ならびにその製造法および使用法
US6074669A (en) Controlled drug delivery system for diltiazem
CA2796884A1 (en) Improved controlled release oral dosage form
KR20080031050A (ko) 높은 ｐｈ-의존성 용해도를 갖는 활성 성분에 대해 활성성분이 ｐｈ-비의존적으로 지연 방출되는 제약 제제
HK1122742A (en) Pharmaceutical form with sustained ph-independent active ingredient release for active ingredients having strong ph-dependent solubility
Kumaravelrajan Development and evaluation of elementary osmotic pump for the simultaneous delivery of nifedipine and metoprolol tartrate
EP1622591A1 (de) Osmotische einkompartimentdarreichungsform zur biphasischen freisetzung von glipizide
WO2006054152A1 (en) Monocompartment osmotic-controlled delivery system of doxazosin
AU2011205024B2 (en) Multiple PPI dosage form
HK1122729B (en) Gastroretentive formulations and manufacturing process thereof

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080227

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20090911

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT

DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER INTELLECTUAL PROPERTY GMBH

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20130722